This study will examine the course of patients with progressive rheumatoid arthritis
associated interstitial lung disease (RA-ILD) treated with rituximab for safety and
progression-free survival at 48 weeks. Safety of rituximab therapy in this disease will be
assessed through patient history, physical exams and laboratory parameters.
- Twelve male/or female patient with RA-associated lung disease (6 of each nonspecific
interstitial pneumonia (NSIP) and usual interstitial pneumonia (UIP) histological
subtype) will be enrolled
- The study involves 12 visits over 48 weeks
- Rituximab will be administered intravenously at Day 1 and Day 15 with repeat dosing at
six months.
Phase:
Phase 3
Details
Lead Sponsor:
Eric Matteson
Collaborators:
Genentech, Inc. National Center for Research Resources (NCRR)